Griseofulvin-Farcos (Liniment) Instructions for Use
Marketing Authorization Holder
Farkos NPF, LLC (Russia)
ATC Code
D01BA01 (Griseofulvin)
Active Substances
Salicylic acid (USP)
Griseofulvin (INN)
Dosage Form
| Griseofulvin-Farcos | Liniment 25 mg+10 mg/1 g: jar 10 g, 15 g, 20 g, or 30 g. |
Dosage Form, Packaging, and Composition
| Liniment | 1 g |
| Griseofulvin | 25 mg |
| Salicylic acid | 10 mg |
10 g – polymer jars (1) – cardboard packs.
15 g – polymer jars (1) – cardboard packs.
20 g – polymer jars (1) – cardboard packs.
30 g – polymer jars (1) – cardboard packs.
Clinical-Pharmacological Group
A drug with antifungal and antiproliferative action for external use
Pharmacotherapeutic Group
Antifungal agent
Pharmacological Action
Combined antifungal agent for external use.
Griseofulvin has a fungistatic effect on various types of dermatophytes (Trichophyton, Microsporum, Epidermophyton). By disrupting the structure of the mitotic spindle, it suppresses the division of fungal cells in metaphase. It accumulates to varying degrees in the cells of the skin, hair, and nails, which are precursors of keratin, making keratin resistant to fungal invasion. As the infected keratin is shed, it is replaced by healthy tissue.
Due to the presence of salicylic acid in the preparation, it penetrates into the deep layers of the affected skin and nail plate. It also has antiseptic and keratolytic effects, reduces itching, and has an analgesic effect.
It does not cause local irritation.
When applied topically, the active components are not absorbed and do not enter the bloodstream, which determines the practical absence of side effects characteristic of the oral use of griseofulvin.
Indications
- Dermatophytosis of the skin, hair, and nails caused by susceptible dermatophytes.
- Fungal infections of the scalp (tinea capitis) and beard area (tinea barbae).
- Onychomycosis affecting the fingernails and toenails.
- Superficial skin mycoses including tinea pedis (athlete’s foot), tinea corporis (ringworm), tinea cruris (jock itch), and tinea manuum (hand fungus).
ICD codes
| ICD-10 code | Indication |
| B35.0 | Mycosis of beard and head |
| B35.1 | Onychomycosis |
| B35.2 | Mycosis of hands |
| B35.3 | Tinea pedis |
| B35.4 | Tinea corporis |
| B35.6 | Tinea cruris |
| ICD-11 code | Indication |
| 1F28.1 | Dermatophytic onychomycosis |
| 1F28.2 | Dermatophytosis of foot |
| 1F28.3 | Genitofemoral dermatophytosis |
| 1F28.Y | Other specified dermatophytosis |
| 1F28.Z | Dermatophytosis, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Apply a thin layer of the liniment to the affected skin areas and gently rub in. Use the preparation twice daily, in the morning and evening.
Before applying to nails, remove the affected parts of the nail plate as much as possible. The maximum daily dose for liniment application should not exceed 20 grams.
Continue treatment for a minimum of 2 weeks after the complete disappearance of clinical symptoms to prevent relapse. The total duration of therapy is determined by the rate of healthy tissue regeneration.
Adverse Reactions
Adverse reactions are infrequent and primarily localized. Allergic reactions may occur, manifesting as skin rash, urticaria, or erythematous rashes at the application site.
In cases of individual hypersensitivity to the components, localized skin irritation, such as redness, peeling, or a burning sensation, may develop. Discontinue use if any adverse reactions occur.
Contraindications
- Hypersensitivity or known allergy to griseofulvin, salicylic acid, or any other component of the formulation.
- Pregnancy at any trimester due to potential teratogenic risks associated with griseofulvin.
- Breastfeeding, as the safety of topical griseofulvin and salicylic acid for the infant has not been established.
- Children under the age of 14 years, as safety and efficacy in this pediatric population have not been confirmed.
Use in Pregnancy and Lactation
Contraindicated during pregnancy and lactation.
Pediatric Use
Use is contraindicated in children under 14 years of age.
Special Precautions
It is not recommended for prophylactic use.
Ethanol intake should be avoided during treatment.
Treatment should continue for at least 2 weeks after the disappearance of clinical symptoms.
If systematic use is necessary, medical supervision is required.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Mildronate capsules 500mg, 90pcs
OKI, sachets 80mg 2g, 12pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Cortexin, 10mg, 5ml, 10pcs
Phenibut-Vertex pills 250mg, 20pcs
Picamilon pills 50mg, 60pcs
Belosalic, ointment, 30g
Kagocel pills 12mg, 30pcs
Actovegin pills 200mg, 50pcs
Fenotropil pills 100mg, 60pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs 